The European Bank for Reconstruction and Development has agreed to invest 6 million euros to support European Metals Holdings' (ASX:EMH) development of the Cinovec lithium project in the Czech Republic. Executive Chairman Keith Coughlan discusses the significance of the placement and the momentum behind lithium in Europe.
Copyright 2023 – Finance News Network
12 Aug 2022 - Magnis Energy Technologies Limited (ASX:MNS) Executive Chairman Frank Poullas discusses the pathway to revenues and increasing capacity as the company's battery gigafactory commences production.
17 Aug 2022 - WT Financial Group Limited (ASX:WTL) Founder and Managing Director Keith Cullen discusses the company's indicative results and the future of financial advice.
13 May 2020 - Elixinol Global (ASX:EXL) CEO, Oliver Horn talks about its strategy to create a global nutraceuticals brand, with a focus on higher margin, consumer branded products, new management team, capital raising and FY 20 outlook.
01 Jun 2020 - NetLinkz Limited (ASX:NET) Executive Chairman & CEO James Tsiolis provides an update on the company's suite of networking solutions, the market opportunity and progress with partners.
25 Jul 2024 - John Borshoff - Managing Director - Deep Yellow (ASX:DYL) is successfully progressing a dual-pillar growth strategy to establish a globally diversified, Tier-1 uranium company to produce 10+ Mlb pa.
04 Dec 2019 - Altech Chemicals Limited (ASX:ATC) Engineering Manager, Mark Griffiths discusses progress with the company's HPA (High Purity Alumina) plant in Malaysia, demand projections, project financing and economics.
17 Aug 2022 - CARETEQ Limited (ASX:CTQ) Executive Chairman Mark Simari discusses the company's recent agreement with drug management platform StrongRoom AI and the transition from paper-based to digital record keeping within the aged care and assistive living sector.
27 Apr 2020 - Kazia Therapeutics (ASX:KZA) CEO & MD, Dr. James Garner talks about its Phase II interim results for its glioblastoma drug candidate paxasilib, its pivotal GBM AGILE Phase II clinical study to commence 2H20 and value drivers as the company moves toward registration.